Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Reviva Pharmaceuticals Holdings, Inc.
Stock-Based Compensation
Reviva Pharmaceuticals Holdings, Inc.
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
|
Stock-Based Compensation
$2.2m
|
CAGR 3-Years
131%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
$1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
$553m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$799m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
$820m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
$626m
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Reviva Pharmaceuticals Holdings, Inc.
Glance View
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.
See Also
What is Reviva Pharmaceuticals Holdings, Inc.'s Stock-Based Compensation?
Stock-Based Compensation
2.2m
USD
Based on the financial report for Dec 31, 2025, Reviva Pharmaceuticals Holdings, Inc.'s Stock-Based Compensation amounts to 2.2m USD.
What is Reviva Pharmaceuticals Holdings, Inc.'s Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
131%
Over the last year, the Stock-Based Compensation growth was 37%. The average annual Stock-Based Compensation growth rates for Reviva Pharmaceuticals Holdings, Inc. have been 131% over the past three years .
